Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics

Expert Review of Molecular Diagnostics

Volumn 11, Issue 1, 2011, Pages 91-100

  Mukhtar, Rita A ^a   Nseyo, Onouwem ^a   Campbell, Michael J ^a   Esserman, Laura J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

alternative activation; breast cancer; leukocyte infiltrate; tumor associated macrophage

Indexed keywords

BIOLOGICAL MARKER; PLASTIC;

ANGIOGENESIS; BREAST CANCER; CANCER DIAGNOSIS; CANCER RISK; CANCER THERAPY; CELL ACTIVATION; HUMAN; IMMUNE RESPONSE; INFLAMMATORY CELL; METASTASIS; NONHUMAN; PHENOTYPE; POLARIZATION; PROGNOSIS; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; WOUND HEALING;

ANIMALS; BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL MOVEMENT; CYTOKINES; FEMALE; HUMANS; MACROPHAGES; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; TUMOR MARKERS, BIOLOGICAL;

EID: 78650547508     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.10.97     Document Type: Review

References (113)

1. Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit. Rev. Oncol. Hematol. 66(1), 1-9 (2008).
2. Cole SW. Chronic inflammation and breast cancer recurrence. J. Clin. Oncol. 27(21), 3418-3419 (2009).
3. de Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7(5), 411-423 (2005).
4. Balkwill F, Mantovani A. Cancer and inflammation: implications for pharmacology and therapeutics. Clin. Pharmacol. Ther. 87(4), 401-406 (2010).
5. Pierce BL, Ballard-Barbash R, Bernstein L et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J. Clin. Oncol. 27(21), 3437-3444 (2009).
6. Terry MB, Gammon MD, Zhang FF et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 291(20), 2433-2440 (2004).
7. Harris RE, Chlebowski RT, Jackson RD et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Womens Health Initiative. Cancer Res. 63(18), 6096-6101 (2003).
8. Pikarsky E, Porat RM, Stein I et al. NF-kB functions as a tumour promoter in inflammation-associated cancer. Nature 431(7007), 461-466 (2004).
9. Greten FR, Eckmann L, Greten TF et al. IKKb links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118(3), 285-296 (2004).
10. Karin M. Nuclear factor-kB in cancer development and progression. Nature 441(7092), 431-436 (2006).
11. Siveen KS, Kuttan G. Role of macrophages in tumour progression. Immunol. Lett. 123(2), 97-102 (2009).
12. Sica A, Larghi P, Mancino A et al. Macrophage polarization in tumour progression. Semin. Cancer Biol. 18(5), 349-355 (2008).
13. Porta C, Larghi P, Rimoldi M et al. Cellular and molecular pathways linking inflammation and cancer. Immunobiology 214(9-10), 761-777 (2009).
14. Zhu X, Mulcahy LA, Mohammed RA et al. IL-17 expression by breast-cancerassociated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res. 10(6), R95 (2008).
15. Hansen BD, Schmidt H, von der Maase H, Sjoegren P, Agger R, Hokland M. Tumour-associated macrophages are related to progression in patients with metastatic melanoma following interleukin-2 based immunotherapy. Acta Oncol. 45(4), 400-405 (2006).
16. Steidl C, Lee T, Shah SP et al. Tumorassociated macrophages and survival in classic Hodgkins lymphoma. N. Engl. J. Med. 362(10), 875-885 (2010).
17. Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancerrelated inflammation. J. Leukoc. Biol. 86(5), 1065-1073 (2009).
18. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifentreated, node-negative breast cancer. N. Engl. J. Med. 351(27), 2817-2826 (2004).
19. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8(12), 958-969 (2008).
20. Mosser DM. The many faces of macrophage activation. J. Leukoc. Biol. 73(2), 209-212 (2003).
21. Khanna S, Biswas S, Shang Y et al. Macrophage dysfunction impairs resolution of inflammation in the wounds of diabetic mice. PLoS ONE 5(3), e9539 (2010).
22. Lucas T, Waisman A, Ranjan R et al. Differential roles of macrophages in diverse phases of skin repair. J. Immunol. 184(7), 3964-3977 (2010).
23. DeNardo DG, Johansson M, Coussens LM. Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev. 27(1), 11-18 (2008).
24. Wan YY. Multi-tasking of helper T cells. Immunology 130(2), 166-171 (2010).
25. Van Ginderachter JA, Movahedi K, Hassanzadeh Ghassabeh G et al. Classical and alternative activation of mononuclear phagocytes: picking the best of both worlds for tumor promotion. Immunobiology 211(6-8), 487-501 (2006).
26. Mantovani A, Sica A, Locati M. Macrophage polarization comes of age. Immunity 23(4), 344-346 (2005).
27. Eriksson F, Tsagozis P, Lundberg K et al. Tumor-specific bacteriophages induce tumor destruction through activation of tumor-associated macrophages. J. Immunol. 182(5), 3105-3111 (2009).
28. Chang HY, Sneddon JB, Alizadeh AA et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol. 2(2), E7 (2004).
29. Troester MA, Lee MH, Carter M et al. Activation of host wound responses in breast cancer microenvironment. Clin. Cancer Res. 15(22), 7020-7028 (2009).
30. Patsialou A, Wyckoff J, Wang Y, Goswami S, Stanley ER, Condeelis JS. Invasion of human breast cancer cells in vivo requires both paracrine and autocrine loops involving the colony-stimulating factor-1 receptor. Cancer Res. 69(24), 9498-9506 (2009).
31. Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur. J. Cancer 42(6), 717-727 (2006).
32. Fujimoto H, Sangai T, Ishii G et al. Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression. Int. J. Cancer 125(6), 1276-1284 (2009).
33. Goswami S, Sahai E, Wyckoff JB et al. Macrophages promote the invasion of breast carcinoma cells via a colonystimulating factor-1/epidermal growth factor paracrine loop. Cancer Res. 65(12), 5278-5283 (2005).
34. Chang M, Hamilton JA, Scholz GM, Masendycz P, Macaulay SL, Elsegood CL. Phosphatidylinostitol-3 kinase and phospholipase C enhance CSF-1-dependent macrophage survival by controlling glucose uptake. Cell Signal. 21, 1361-1369 (2009).
35. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 193(6), 727-740 (2001).
36. Puig-Kroger A, Sierra-Filardi E, Dominguez-Soto A et al. Folate receptor b is expressed by tumor-associated macrophages and constitutes a marker for M2 anti-inflammatory/regulatory macrophages. Cancer Res. 69(24), 9395-9403 (2009).
37. Eubank TD, Galloway M, Montague CM, Waldman WJ, Marsh CB. M-CSF induces vascular endothelial growth factor production and angiogenic activity from human monocytes. J. Immunol. 171(5), 2637-2643 (2003).
38. Lewis CE, Leek R, Harris A, McGee JO. Cytokine regulation of angiogenesis in breast cancer: the role of tumor-associated macrophages. J. Leukoc. Biol. 57(5), 747-751 (1995).
39. Lin EY, Pollard JW. Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res. 67(11), 5064-5066 (2007).
40. Lin EY, Li JF, Gnatovskiy L et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res. 66(23), 11238-11246 (2006).
41. Vicioso L, Gonzalez FJ, Alvarez M et al. Elevated serum levels of vascular endothelial growth factor are associated with tumor-associated macrophages in primary breast cancer. Am. J. Clin. Pathol. 125(1), 111-118 (2006).
42. Qian B, Deng Y, Im JH et al. A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS ONE 4(8), e6562 (2009).
43. Sinha P, Clements VK, Miller S, Ostrand-Rosenberg S. Tumor immunity: a balancing act between T cell activation, macrophage activation and tumorinduced immune suppression. Cancer Immunol. Immunother. 54(11), 1137-1142 (2005).
44. Galmbacher K, Heisig M, Hotz C et al. Shigella mediated depletion of macrophages in a murine breast cancer model is associated with tumor regression. PLoS ONE 5(3), e9572 (2010).
45. Lu X, Kang Y. Chemokine (C-C motif ) ligand 2 engages CCR2+ stromal cells of monocytic origin to promote breast cancer metastasis to lung and bone. J. Biol. Chem. 284(42), 29087-29096 (2009).
46. Aharinejad S, Paulus P, Sioud M et al. Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Res. 64(15), 5378-5384 (2004).
47. Ueno T, Toi M, Saji H et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin. Cancer Res. 6(8), 3282-3289 (2000).
48. Watkins SK, Li B, Richardson KS et al. Rapid release of cytoplasmic IL-15 from tumor-associated macrophages is an initial and critical event in IL-12-initiated tumor regression. Eur. J. Immunol. 39(8), 2126-2135 (2009).
49. Talmadge JE, Donkor M, Scholar E. Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev. 26(3-4), 373-400 (2007).
50. Lewis CE, Hughes R. Inflammation and breast cancer. Microenvironmental factors regulating macrophage function in breast tumours: hypoxia and angiopoietin-2. Breast Cancer Res. 9(3), 209 (2007).
51. Hagemann T, Lawrence T, McNeish I et al. Re-educating tumor-associated macrophages by targeting NF-kB. J. Exp. Med. 205(6), 1261-1268 (2008).
52. Knowles H, Leek R, Harris AL. Macrophage infiltration and angiogenesis in human malignancy. Novartis Found Symp. 256, 189-200 (2004).
53. Shirakawa K, Tsuda H, Heike Y et al. Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res. 61(2), 445-451 (2001).
54. Eubank TD, Roberts RD, Khan M et al. Granulocyte macrophage colonystimulating factor inhibits breast cancer growth and metastasis by invoking an anti-angiogenic program in tumoreducated macrophages. Cancer Res. 69(5), 2133-2140 (2009).
55. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9(11), 798-809 (2009).
56. Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 65(8), 3437-3446 (2005).
57. Kuroda E, Ho V, Ruschmann J et al. SHIP represses the generation of IL-3-induced M2 macrophages by inhibiting IL-4 production from basophils. J. Immunol. 183(6), 3652-3660 (2009).
58. Hagemann T, Biswas SK, Lawrence T, Sica A, Lewis CE. Regulation of macrophage function in tumors: the multifaceted role of NF-kB. Blood 113(14), 3139-3146 (2009).
59. Sica A, Saccani A, Bottazzi B et al. Autocrine production of IL-10 mediates defective IL-12 production and NF-kB activation in tumor-associated macrophages. J. Immunol. 164(2), 762-767 (2000).
60. Porta C, Rimoldi M, Raes G et al. Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor kB. Proc. Natl Acad. Sci. USA 106(35), 14978-14983 (2009).
61. Saccani A, Schioppa T, Porta C et al. p50 nuclear factor-kB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res. 66(23), 11432-11440 (2006).
62. Biswas SK, Gangi L, Paul S et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kB and enhanced IRF-3/STAT1 activation). Blood 107(5), 2112-2122 (2006).
63. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J. Immunol. 179(2), 977-983 (2007).
64. Mantovani A, Allavena P, Sica A. Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. Eur. J. Cancer 40(11), 1660-1667 (2004).
65. DeNardo DG, Barreto JB, Andreu P et al. CD4+ T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell. 16(2), 91-102 (2009).
66. Luo Y, Zhou H, Krueger J et al. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J. Clin. Invest. 116(8), 2132-2141 (2006).
67. Huber S, Hoffmann R, Muskens F, Voehringer D. Alternatively activated macrophages inhibit T cell proliferation by STAT6-dependent expression of PD-L2. Blood 116(17), 3311-3320 (2010).
68. Wong SC, Puaux AL, Chittezhath M et al. Macrophage polarization to a unique phenotype driven by B cells. Eur. J. Immunol. 40(8), 2296-2307 (2010).
69. Demaria S, Volm MD, Shapiro RL et al. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin. Cancer Res. 7(10), 3025-3030 (2001).
70. Steele RJ, Eremin O, Brown M, Hawkins RA. A high macrophage content in human breast cancer is not associated with favourable prognostic factors. Br. J. Surg. 71(6), 456-458 (1984).
71. Steele RJ, Brown M, Eremin O. Characterisation of macrophages infiltrating human mammary carcinomas. Br. J. Cancer 51(1), 135-138 (1985).
72. Volodko N, Rudas M, Jakesz R. Tumourassociated macrophages in breast cancer and their prognostic correlations. Breast 7(2), 99-105 (1998).
73. Gottfried E, Kunz-Schughart LA, Weber A et al. Expression of CD68 in non-myeloid cell types. Scand. J. Immunol. 67(5), 453-463 (2008).
74. Leek RD, Landers RJ, Harris AL, Lewis CE. Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br. J. Cancer 79(5-6), 991-995 (1999).
75. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 56(20), 4625-4629 (1996).
76. Leek RD, Hunt NC, Landers RJ, Lewis CE, Royds JA, Harris AL. Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J. Pathol. 190(4), 430-436 (2000).
77. Murri AM, Hilmy M, Bell J et al. The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic and macrophage infiltration, microvessel density and survival in patients with primary operable breast cancer. Br. J. Cancer 99(7), 1013-1019 (2008).
78. Visscher DW, Tabaczka P, Long D, Crissman JD. Clinicopathologic analysis of macrophage infiltrates in breast carcinoma. Pathol. Res. Pract. 191(11), 1133-1139 (1995).
79. Bolat F, Kayaselcuk F, Nursal TZ, Yagmurdur MC, Bal N, Demirhan B. Microvessel density, VEGF expression, and tumor-associated macrophages in breast tumors: correlations with prognostic parameters. J. Exp. Clin. Cancer Res. 25(3), 365-372 (2006).
80. Cummings TJ, Hulette CM, Bigner SH, Riggins GJ, McLendon RE. Ham56- immunoreactive macrophages in untreated infiltrating gliomas. Arch. Pathol. Lab. Med. 125(5), 637-641 (2001).
81. Esserman LJ, Kumar AS, Herrera AF et al. Magnetic resonance imaging captures the biology of ductal carcinoma in situ. J. Clin. Oncol. 24(28), 4603-4610 (2006).
82. Leonardi E, Girlando S, Serio G et al. PCNA and Ki67 expression in breast carcinoma: correlations with clinical and biological variables. J. Clin. Pathol. 45(5), 416-419 (1992).
83. Isbel NM, Nikolic-Paterson DJ, Hill PA, Dowling J, Atkins RC. Local macrophage proliferation correlates with increased renal M-CSF expression in human glomerulonephritis. Nephrol. Dial. Transplant. 16(8), 1638-1647 (2001).
84. Zenger E, Abbey NW, Weinstein MD et al. Injection of human primary effusion lymphoma cells or associated macrophages into severe combined immunodeficient mice causes murine lymphomas. Cancer Res. 62(19), 5536-5542 (2002).
85. Martin DN, Boersma BJ, Yi M et al. Differences in the tumor microenvironment between African-American and European- American breast cancer patients. PLoS ONE 4(2), e4531 (2009).
86. Zaloznik AJ. Breast cancer stage at diagnosis: Caucasians versus Hispanics. Breast Cancer Res. Treat. 42(2), 121-124 (1997).
87. Patel TA, Colon-Otero G, Bueno Hume C, Copland JA 3rd, Perez EA. Breast cancer in Latinas: gene expression, differential response to treatments, and differential toxicities in Latinas compared with other population groups. Oncologist 15(5), 466-475 (2010).
88. Mukhtar R, Moore A, Nseyo O et al. Evaluation of levels of proliferating macrophages in patients at a county hospital and those with early recurrences. Presented at: ASCO Annual Meeting Proceedings. Chicago, IL, USA, 4-8 June 2010.
89. Lyons TR, Schedin PJ, Borges VF. Pregnancy and breast cancer: when they collide. J. Mammary Gland Biol. Neoplasia 14(2), 87-98 (2009).
90. OBrien J, Lyons T, Monks J et al. Alternatively activated macrophages and collagen remodeling characterize the postpartum involuting mammary gland across species. Am. J. Pathol. 176(3), 1241-1255 (2010).
91. OBrien J, Schedin P. Macrophages in breast cancer: do involution macrophages account for the poor prognosis of pregnancy-associated breast cancer? J. Mammary Gland Biol. Neoplasia 14(2), 145-157 (2009).
92. Shabo I, Stal O, Olsson H, Dore S, Svanvik J. Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival. Int. J. Cancer 123(4), 780-786 (2008).
93. Raes G, Brys L, Dahal BK et al. Macrophage galactose-type C-type lectins as novel markers for alternatively activated macrophages elicited by parasitic infections and allergic airway inflammation. J. Leukoc. Biol. 77(3), 321-327 (2005).
94. Lopez-Beltran A, Requena MJ, Alvarez- Kindelan J, Quintero A, Blanca A, Montironi R. Squamous differentiation in primary urothelial carcinoma of the urinary tract as seen by MAC387 immunohistochemistry. J. Clin. Pathol. 60(3), 332-335 (2007).
95. Kluger HM, Dolled-Filhart M, Rodov S, Kacinski BM, Camp RL, Rimm DL. Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis. Clin. Cancer Res. 10(1 Pt 1), 173-177 (2004).
96. Mantovani A. La mala educacin of tumor-associated macrophages: diverse pathways and new players. Cancer Cell 17(2), 111-112 (2010).
97. Dewar AL, Cambareri AC, Zannettino AC et al. Macrophage colony-stimulating factor receptor c-Fms is a novel target of imatinib. Blood 105(8), 3127-3132 (2005).
98. Hiraga T, Nakamura H. Imatinib mesylate suppresses bone metastases of breast cancer by inhibiting osteoclasts through the blockade of c-Fms signals. Int. J. Cancer 124(1), 215-222 (2009).
99. Ohno H, Kubo K, Murooka H et al. A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol. Cancer Ther. 5(11), 2634-2643 (2006).
100. Manthey CL, Johnson DL, Illig CR et al. JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/ FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. Mol. Cancer Ther. 8(11), 3151-3161 (2009).
101. Campbell MJ, Scott J, Maecker HT, Park JW, Esserman LJ. Immune dysfunction and micrometastases in women with breast cancer. Breast Cancer Res. Treat. 91(2), 163-171 (2005).
102. Sista AK, Knebel RJ, Tavri S et al. Optical imaging of the peri-tumoral inflammatory response in breast cancer. J. Transl. Med. 7, 2009
103. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin. Pharmacol. Ther. 86(1), 97-100 (2009).
104. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 5(12), 953-964 (2005).
105. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 117(5), 1155-1166 (2007).
106. Chang YC, Chen TC, Lee CT et al. Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3. Blood 111(10), 5054-5063 (2008).
107. Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H, Yu H. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J. Clin. Invest. 118(10), 3367-3377 (2008).
108. McNally AK, DeFife KM, Anderson JM. Interleukin-4-induced macrophage fusion is prevented by inhibitors of mannose receptor activity. Am. J. Pathol. 149(3), 975-985 (1996).
109. Barreda DR, Hanington PC, Belosevic M. Regulation of myeloid development and function by colony stimulating factors. Dev. Comp. Immunol. 28(5), 509-554 (2004).
110. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23(11), 549-555 (2002).
111. Stout RD, Watkins SK, Suttles J. Functional plasticity of macrophages: in situ reprogramming of tumor-associated macrophages. J. Leukoc. Biol. 86(5), 1105-109 (2009).
112. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25(12), 677-686 (2004).
113. Germano G, Allavena P, Mantovani A. Cytokines as a key component of cancerrelated inflammation. Cytokine 43(3), 374-379 (2008)